Key takeaways
- 1,200-1,500 Epidemiology-based estimate of true GCC HAE patients (~1:50,000 prevalence applied to ~75M population)
- <200 Confirmed HAE cases across all six GCC states, KFSH&RC HAE Registry, the region's most complete clinical source
- 400-600 GCC HAE launch-planning population estimate, of which 350-500 are never-prophylaxed
- 6-10 Total HAE specialist physicians across the entire GCC, the diagnostic-capacity constraint behind the registry/epidemiology gap
Epidemiology implies 1,200-1,500 true GCC HAE patients; the KFSH&RC registry confirms fewer than 200; and a separate planning estimate lands at 400-600 — the gap across all three traces to a 6-10-physician specialist bottleneck.
Three independent methods size the GCC HAE population, and they diverge for a specific, sourced reason rather than measurement error. The epidemiology method applies the standard background HAE prevalence, roughly 1 in 50,000, to the GCC's approximately 75 million population, implying 1,200 to 1,500 true patients. The registry method counts confirmed diagnoses: the KFSH&RC HAE Registry, the region's most complete clinical source, documents fewer than 200 confirmed cases across all six GCC states. A third figure, used specifically in GCC launch-planning work rather than epidemiological modelling, estimates 400 to 600 total patients, of whom 350 to 500 are never-prophylaxed.
The gap across all three numbers traces to a single, verifiable constraint: the entire GCC HAE specialist community numbers only six to ten physicians, concentrated at KFSH&RC and a handful of other tertiary centres, and SERPING1 genetic testing plus C1-INH functional assays are similarly concentrated. An estimated 30 to 50 percent of true HAE burden remains undiagnosed as a direct result, and abdominal attacks, which account for 50 to 70 percent of all HAE episodes, are frequently misdiagnosed in GCC as gastroenteritis, appendicitis or a gynaecological condition, driving an estimated 30 to 40 percent of GCC HAE patients toward unnecessary abdominal surgery before correct diagnosis. Triangulating the three figures does not average them into one number. It identifies diagnostic capacity, not prevalence rate, as the single assumption that determines how large the addressable population actually is, and ranks it above every other sizing input in the sensitivity analysis.
GCC HAE sizing — three methods, one diagnostic-capacity gap
| Sizing Method | Population Estimate | Source |
|---|---|---|
| Epidemiology-based (~1:50,000 prevalence) | 1,200-1,500 patients | Applied to ~75M GCC population |
| Registry-based (confirmed diagnoses) | <200 patients | KFSH&RC HAE Registry 2022 |
| Launch-planning estimate | 400-600 patients (350-500 never-prophylaxed) | GCC allergy/immunology society HAE case registry |
| Diagnostic capacity constraint | 6-10 HAE specialist physicians, GCC-wide | SACIA membership directory |
Sources: KFSH&RC HAE Registry 2022; Al-Hamdi K, Ann Allergy Asthma Immunol 2020; GCC allergy/immunology society HAE case registry; Saudi Allergy Society clinical meeting 2023; SACIA membership directory.
What this model answers
Every section answers a named commercial question your team is asking, scoped to your asset.
- Why do epidemiology (1,200-1,500), registry (<200) and launch-planning (400-600) estimates diverge so sharply, and which should a forecast use? • All three methods explained and sourced • the diagnostic-capacity constraint (6-10 specialists) as the unifying explanation • guidance on which figure fits a given commercial use case
- How does diagnostic capacity, rather than prevalence rate, rank as the single assumption most likely to move the sized total? • Sensitivity ranking of every input • the specialist-physician and testing-lab bottleneck quantified • the undiagnosed-patient estimate (30-50%) this implies
- What would it take to move the addressable GCC HAE population from the 400-600 planning estimate toward the 1,200-1,500 epidemiology-implied total? • Diagnostic-capacity expansion scenarios • abdominal-attack misdiagnosis pathway mapping • the addressable-population uplift each scenario would unlock
What's inside
-
1 · The Binding Constraint 2 pp
- Why diagnostic capacity, not prevalence rate, is the single assumption that determines whether any of the three totals hold up
- Pressure-tested against the epidemiology-vs-registry gap before the model is built out
-
2 · Epidemiology-Based Sizing 3 pp
- Global HAE prevalence rate (~1:50,000) applied to the GCC population
- The 1,200-1,500 total-patient estimate this implies
-
3 · Registry-Based Sizing — KFSH&RC 3 pp
- KFSH&RC HAE Registry confirmed-case count (<200) and its methodology
- Cross-check against the epidemiology-based estimate
-
4 · Launch-Planning Estimate & the Never-Prophylaxed Cohort 3 pp
- The 400-600 planning total and the 350-500 never-prophylaxed subset
- Why this figure differs from both epidemiology and registry counts
-
5 · Triangulation, Diagnostic Capacity & Sensitivity 3 pp
- The 6-10-specialist bottleneck ranked above prevalence rate as the binding assumption
- Scenario ranges tied to diagnostic-capacity expansion
-
6 · Editable Excel Model —
- The full triangulated model, re-runnable with your own assumptions
-
7 · Client Alignment Questions 2 pp
- The open sizing questions your team must close before the number is used in planning
Appendix and source ledger included · 45-minute analyst readout included with delivery
Custom model delivered in 72 hours.
Assess this reportIncluded with every brief
Get Started
Commission this model
AXLRx delivers rare disease market sizing models built for forecasting and strategy teams sizing the GCC HAE opportunity. Custom model in 72 hours.
- 1. Submit your requestSpecify your indication, target GCC country, and cohort definition.
- 2. Scoping callAXLRx analyst confirms triangulation methods and comparator set before building.
- 3. DeliveryResearch-verified sizing model in 72 hours with optional analyst readout.
How AXLRx builds this model
Prepared by MoatRx analysts on the AXLRx commercial consulting engine.
Every AXLRx market sizing model triangulates at least two independent methods, epidemiology-based and registry-based, before accepting a patient count. This is explicitly a sizing model (static patient count), distinct from a Launch Readiness or forecasting model (dynamic revenue/uptake).
GCC HAE sizing sources: KFSH&RC HAE Registry 2022, Al-Hamdi K (Ann Allergy Asthma Immunol 2020), the GCC allergy/immunology society HAE case registry and Saudi Allergy Society clinical meeting 2023 for the launch-planning estimate, and the SACIA membership directory for the specialist-physician count.
- KFSH&RC confirmed-case count (<200) verified against the KFSH&RC HAE Registry 2022
- Epidemiology-based estimate (1,200-1,500) verified against Al-Hamdi K, Ann Allergy Asthma Immunol 2020, applied to the GCC population
- Launch-planning estimate (400-600) and the 6-10-specialist bottleneck verified against the GCC allergy/immunology society HAE case registry and the SACIA membership directory
Frequently asked questions
Deliverables What formats are included with every model?
Every commissioned Market Sizing Model includes an editable 5-sheet Excel model (Cover, Model, Research Validation, QC, Sensitivity) and a PDF methodology brief, no PowerPoint deck. An optional 45-minute analyst readout call is included.
Sources How is the patient count verified?
AXLRx triangulates every sizing estimate across at least two independent methods, epidemiology-based and registry-based, and names the diagnostic-capacity constraint explaining any gap rather than picking a single unverified number.
Customisation Can I size a specific GCC market or subpopulation?
Yes. The intake form captures your indication, target GCC country, and cohort definition. A scoping call confirms scope before research starts. Commission via the intake form to start.